论文信息 - What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia? - 字舞流文

What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?

C. Flowers | S. Ramsey

[1] S. Ramsey,et al. Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure. , 2016, Health affairs.

[2] J. Radich,et al. What Happens When Imatinib Goes Generic? , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[3] C. Flowers,et al. Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost. , 2015, JAMA oncology.

[4] P. Newcomb,et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. , 2013, Health affairs.

[5] S. Ramsey,et al. Cost–effectiveness of prostate cancer chemoprevention among high-risk men , 2010, Expert review of pharmacoeconomics & outcomes research.